Searched for
CADILA SHARES
For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Sell Cadila Healthcare, target price Rs 377: ICICI DirectCadila Healthcare Ltd., incorporated in the year 1995, is a Large Cap company (having a market cap of Rs 40816.62 Crore) operating in Pharm...
- Will three-dose Covid vaccine give Cadila Healthcare a booster shot?Analysts do see a lift to its sales, even as some of them are not factoring in sales beyond FY23 amid uncertainty over booster shots. The p...
- Cadila extends tenure of joint venture with Bayer PteCadila Healthcare said it has signed an agreement to extend the tenure of the joint venture with a Bayer Group firm for a period of two mon...
- Cadila share slips 5% after deal with HeinzZydus Wellness had on Wednesday said it will acquire Heinz India.
- Cadila up 2% as Gujarat plant gets no USFDA observationThe company had recently reported 53.26 per cent jump in consolidated net profit at Rs 590.8 crore.
- Zydus Cadila gets USFDA nod for prostate condition treatment drugThe drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH) -- also called prostate gland enlargement.
- Buy Cadila Healthcare, target Rs 415: Sagar DoshiBuy Cadila Healthcare Ltd. at a price target of Rs 415.0 and a stop loss at Rs 380 from entry point.
- Buy Cadila Healthcare, target Rs 444: Equirus SecuritiesBuy Cadila Healthcare Ltd. at a price target of Rs 444.0 .
- Cadila Healthcare soars over 4% post USFDA drug nodCLSA has upgraded Cadila Healthcare to ‘buy’ from ‘underperform’.
- CLSA upgrades Cadila Healthcare to 'buy'Shares of Cadila ended down 1.74 per cent at Rs 369.95 on the BSE on Friday.
- Cadila Healthcare falls after coming under CDSCO scannerThe scrip touched its fresh 52-week high of Rs 558 on June 12, 2017 and its 52-week low of Rs 329.95 on December 26, 2016.
- Zydus Cadila gets USFDA nod for blood pressure drugWith the latest approvals from the USFDA, the group now has more than 140 approvals and has so far filed over 300 abbreviated new drug appl...
- Zydus Cadila gets USFDA nod for ezetimibe tabletsThe group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs), the company said.
- Cadila shares jump 9.5% despite disappointing Q1 showShrugging off the disappointing numbers, the drug firm's scrip opened the day on a positive note and further jumped 9.48 per cent to Rs 379...
- Cadila Healthcare to delist from Ahmedabad Stock Exchange, will remain listed on BSE and NSEThe company's board, which met today, decided to delist equity shares of the company from ASE, Cadila Healthcare said in a filing to the BS...
- Cadila Health is a buy call with a target of Rs 1100: Mitesh ThackerCadila Health is a 'BUY' call with a target of Rs 1100 and a stop loss of Rs 1024.
- Zydus Cadila Group to merge its three subsidiaries with its listed entity Cadila Healthcare LtdIn 2000, Zydus Cadila had created a strategic alliance with Ambalal Sarabhai Enterprises to integrate the animal healthcare business of bot...
- Cadila shareholders approve share swap for biz restructuringPharmaceutical firm Cadila Healthcare said its shareholders have approved the restructuring of its consumer products division as subsidiary...
Load More
